

FP USA Will Leverage Global Operations Footprint



R&D Innovation

- 4 core technology platforms
- 7 core therapeutic areas
- 3400+ R&D staff
- 70+ in-progress innovative drug and biosimilar projects (by indication)

Manufacturing System


- Vertical integration of the chemical API and formulation, clustering to the advantageous manufacturing capacity
- Commercialized production capacity of 48,000L for biologics
- 100+ official inspections
- 600+ batches of official sampling
- 9 manufacturing lines have passed GMP certification of US FDA, EU and other markets



Commercialization System

- Professionalization, branding, digitalization, compliance
- ~5,000 commercialization staffs in China
- ~1,000 overseas commercialization staffs
- Continuous optimization of marketing compliance management system

FP USA Will Leverage Global Operations Footprint



International Standard Manufacturing

- 10+ production lines for API and formulation of Yao Pharma, Wanbang and Guilin Pharma received GMP certifications from the U.S., Europe, etc.
- Integrating manufacturing facilities to improve efficiency, accelerating the construction of Xuzhou Industrial Park Formulation Plant and of API facilities in Changsha, Xuzhou and Chongqing
- Commercialization capacity of Henlius is 48,000L now and will reach 144,000L in 2026; Xuhui plant has passed dual GMP certification in both China and Europe
- Fosun Adgenvax received Drug Manufacturing License and the Drug Operation Licence, supporting its subsequent commercialization of in-line vaccine products
- Constructing the Côte d'Ivoire Industrial Park in order to achieve localizing products manufacturing and distributing in Africa
- Gland Pharma received GMP certifications from the U.S., EU, Japan, Australia, etc.; Gland Pharma fully acquired Cenexi and entered into Europe-based CDMO

Plant	Date	Product	Progress
Henlius Songjiang (1 st Plant)	Aug '23	Trastuzumab injection (HER2)	Accept FDA Pre-approval test
Henlius Xuhui	Oct '23	Serplulimab Injection (PD-1)	Passed Indonesian BPOM GMP inspection
Henlius Xuhui	Oct '23	Serplulimab Injection (PD-1), Trastuzumab injection (HER2)	Passed Brazilian ANVISA inspection
Henlius Xuhui	Nov '23	Rituximab injection (CD20) DS&DP	Passed Colombian INVIMA inspection
Henlius Xuhui & Songjiang(1 st Plant)	Dec '23	Serplulimab Injection (PD-1)	Obtained EU GMP certificates
Guilin Pharma	Oct '23	Sertraline Hydrochloride Tablets and Compound Sulfamethoxazole Tablets	Passed FDA Pre-Approval Inspection